Gene editing technologies give researchers and clinicians the ability to make precise, targeted changes directly to an organism’s DNA — adding, removing, or altering specific locations in the genome rather than simply introducing new genetic material alongside the existing sequence, as classic gene therapy does. Three technologies have driven the field’s progress from research tool to approved clinical therapy: CRISPR-Cas9, zinc finger nucleases, and TALENs. Understanding how each works, how they differ, and how they’re actually being used therapeutically is foundational to following where cell and gene therapy is headed next.
How Does Gene Editing Actually Work at the Molecular Level?
Gene editing works by using engineered molecular tools to introduce precise, targeted breaks in a cell’s DNA at a specific genomic location, which the cell’s own repair machinery then resolves — either by simply rejoining the break, which can disrupt or “knock out” a gene’s function, or by using a provided donor DNA template to repair the break with a specific, intended new sequence, which allows researchers to correct a mutation or insert new genetic material at a precise location. A complete gene editing system typically requires three components working together: a nuclease, the molecular “scissors” that creates the targeted DNA break; a DNA-targeting element that directs the nuclease to the correct genomic location; and, where a specific sequence change is intended rather than simple disruption, a donor DNA template providing the repair sequence.
What Is CRISPR-Cas9, and Why Has It Become the Dominant Gene Editing Platform?
CRISPR-Cas9 — short for clustered regularly interspaced short palindromic repeats, paired with the CRISPR-associated protein 9 — is a naturally occurring bacterial defense mechanism against viral invaders, repurposed as a programmable gene editing tool. In its natural bacterial context, CRISPR sequences store fragments of DNA from past viral invaders, allowing the bacterium to recognize and destroy the same virus if it returns; researchers have adapted this mechanism by designing a synthetic guide RNA that directs the Cas9 enzyme to cut a specific, chosen sequence anywhere in a genome, rather than only sequences matching a bacterium’s accumulated viral memory.
CRISPR-Cas9 has become the dominant gene editing platform because of its comparative simplicity, flexibility, and efficiency: redirecting the system to target a new genomic location requires only designing a new guide RNA sequence, a relatively fast and inexpensive process compared to the alternative platforms discussed below. CRISPR-Cas9 has treated diseases including sickle cell disease and beta-thalassemia in approved commercial therapies, and remains the most heavily represented editing platform in active clinical development, with trial activity in this category growing roughly 400 percent in recent years as the technology extends into a broader range of target diseases.
How Do Zinc Finger Nucleases and TALENs Differ From CRISPR?
Zinc finger nucleases, or ZFNs, are artificial restriction enzymes that pair DNA-binding zinc finger proteins with a DNA-cleaving domain. Where naturally occurring restriction enzymes typically recognize short DNA sequences of only four to eight base pairs — short enough that they risk binding and cutting unintended, similar sequences elsewhere in the genome — ZFNs are engineered to recognize considerably longer sequences, generally nine to eighteen base pairs, providing greater targeting specificity than naturally occurring restriction enzymes alone could achieve.
TALENs, or transcription activator-like effector nucleases, take a related approach, pairing DNA-binding proteins called transcription activator-like effectors with the FokI cleavage enzyme to create a targeted DNA break. Both ZFNs and TALENs predate CRISPR-Cas9’s emergence as a widely used research and therapeutic tool, and both have been used to modify genes in early-stage research and therapeutic development, including applications in HIV and cancer treatment. Compared to CRISPR-Cas9, both platforms generally require more complex, time-intensive engineering to redesign for each new target sequence, since redirecting them to a new genomic location requires re-engineering the actual DNA-binding protein structure rather than simply designing a new guide RNA — a meaningful practical disadvantage that has contributed to CRISPR-Cas9’s dominance in newer development programs, even as ZFN and TALEN platforms remain in active use for specific applications where they were already established.
What Does an Approved Gene Editing Therapy Look Like in Practice?
Casgevy, approved by the FDA in December 2023, illustrates how CRISPR-Cas9 editing translates into an actual clinical therapy. Developed for sickle cell disease, Casgevy uses CRISPR-Cas9 to edit a patient’s own hematopoietic stem cells outside the body, modifying a specific genetic switch that controls production of fetal hemoglobin — a form of hemoglobin that doesn’t carry the mutation responsible for sickle cell disease. The edited cells are then reinfused into the patient, where they engraft in the bone marrow and begin producing red blood cells with reduced sickle hemoglobin, addressing the disease’s underlying genetic cause directly rather than managing its symptoms.
This approval represented the first FDA-authorized treatment using CRISPR-based gene editing technology, and clinical results have been substantial: in supporting trial data, the large majority of treated patients achieved freedom from the severe, recurrent pain crises that characterize sickle cell disease at twelve or more months following treatment.
What Other Therapeutic Applications Is Gene Editing Being Explored For?
Beyond sickle cell disease, gene editing is being actively explored across a widening range of therapeutic applications. In oncology, gene editing is used both to engineer next-generation CAR-T cell products — disrupting genes that would otherwise limit a CAR-T cell’s persistence or function — and as a research tool to identify genes contributing to treatment resistance. In cardiovascular and metabolic disease, base editing approaches, a refinement of CRISPR technology that makes precise single-letter DNA changes without creating a double-strand break, have shown substantial reductions in disease-driving proteins in early clinical trials, including meaningful LDL cholesterol reduction in a base-editing approach targeting familial hypercholesterolemia.
Newer delivery approaches are also expanding what’s possible therapeutically. Lipid nanoparticle delivery of gene editing components directly into the body — rather than editing cells outside the body and reinfusing them — has enabled in vivo editing applications for diseases like hereditary ATTR amyloidosis, where one early approach demonstrated substantial reduction in the disease-causing protein through a single in vivo treatment, expanding gene editing’s reach beyond conditions where ex vivo cell collection and modification is practical.
What Should Be Understood About Gene Editing’s Current Limitations?
Despite this progress, gene editing carries risks and limitations that shape how cautiously the field continues to advance. In vivo editing in particular is, by its nature, difficult to reverse once administered — unlike a conventional drug that’s metabolized and cleared, an edited genetic sequence remains permanently altered, which places a high premium on getting target selection and editing precision right before a therapy reaches patients. Off-target editing — the gene editing system cutting at unintended genomic locations beyond its intended target — remains an active area of safety monitoring and ongoing technology refinement across all major editing platforms, and long-term safety monitoring requirements for approved and investigational gene editing therapies reflect genuine, still-developing understanding of what permanent genomic modification means over a patient’s full lifetime, not merely the years immediately following treatment.